Physician profile
Meredith C Starr
NPI 1538699855
$1,111.58
in general payments reported to CMS, 2019-2025
14 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.15 · 2024: $278 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.11 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $163.71 | 2025 | |
| Pfizer INC. | $148.93 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $126.87 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Xeris Pharmaceuticals, INC. | $94.74 | 2025 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.70 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $72.14 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.05 | 2025 | Xifaxan |
| Amgen INC. | $68.19 | 2024 | Otezla, Repatha |
| Neos Therapeutics, LP | $18.02 | 2024 | Adzenys Xr-Odt |
| Stryker Corporation | $16.10 | 2025 | Clottriever Bold Catheter |
| Lilly USA, LLC | $16.01 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2024 | Trintellix |
| Therapeuticsmd, INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.